Arthneeti

Nephro Care India Share Price & Earnings Call Analysis

₹79.10-3.12% today
Market cap
₹130 Cr
P/E
25.77
ROE
5.07%
PEG
4.51
Price to sales
1.47
Debt to equity
0.00
52W high / low
₹151 / ₹51.8
Sales growth (5Y)
117.58%
EBITDA margin
9.38%
Net profit margin
3.16%
Promoter holding
61.71%
Sales (last year)
₹89 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Aster DM Quality Care LtdGood growth
    3
See all potential multibaggersWhere does Nephro Care rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹921 Cr—
240%+Flat₹575 Cr21.9
3Aster DM Quality Care Ltd20–40%Up 2%+₹59,405 Cr164.6
420–40%Up 2%+₹551 Cr18.5
520–40%Up 0–2%₹1,635 Cr16.5
620–40%Flat₹1.21L Cr57.7

Sign up free to see every company in the sector ranking and track Nephro Care.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Nephro Care

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Nephro Care

Quarterly Results

Quarter-by-quarter operating performance

Dec 2025Mar 2026
Sales +22.6626.75
Expenses +20.7524.73
Operating Profit1.912.02
OPM %8.43%7.55%
Other Income +0.080.83
Interest0.03-0.01
Depreciation1.401.56
Profit before tax0.561.30
Tax %25.00%23.08%
Net Profit +0.421.00
EPS in Rs0.250.61

Financials of Nephro Care

Profit & Loss

Annual income statement trend

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +0.541.823.4217.0927.2346.0388.73
Expenses +0.521.673.2813.6620.7640.1680.41
Operating Profit0.020.150.143.436.475.878.32
OPM %3.70%8.24%4.09%20.07%23.76%12.75%9.38%
Other Income +0.010.01-0.010.000.281.531.55
Interest0.040.030.020.070.090.110.16
Depreciation0.000.010.110.780.532.465.07
Profit before tax-0.010.120.002.586.134.834.64
Tax %0.00%25.00%7.75%28.06%24.64%27.37%
Net Profit +-0.010.09-0.012.374.413.643.37
EPS in Rs-10.0090.00-0.2047.403.712.212.04
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Nephro Care

Balance Sheet

Capital structure and asset base

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital0.010.010.500.5011.9016.4916.49
Reserves0.070.010.002.033.1237.0040.37
Borrowings +0.400.692.542.480.000.000.00
Other Liabilities +0.300.421.603.255.9414.7915.81
Total Liabilities0.781.134.648.2620.9668.2872.67
Fixed Assets +0.450.061.393.014.7431.4834.12
CWIP0.000.451.900.000.860.610.43
Investments0.240.000.002.006.5118.5811.82
Other Assets +0.090.621.353.258.8517.6126.30
Total Assets0.781.134.648.2620.9668.2872.67

Financials of Nephro Care

Cash Flows

Operating, investing and financing cash movement

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +0.230.624.120.917.82
Cash from Investing Activity +-0.06-2.81-2.33-7.54-39.56
Cash from Financing Activity +0.282.32-0.085.6035.10
Net Cash Flow0.440.131.71-1.033.37
Free Cash Flow0.16-2.283.62-2.38-21.98
CFO/OP133%493%121%50%154%

Financials of Nephro Care

Ratios

Working capital efficiency and return ratios

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days0.000.0020.280.852.0125.6124.85
Inventory Days8.8341.9335.2514.0734.3831.68
Days Payable94.19113.4569.0375.17107.3292.84
Cash Conversion Cycle0.00-85.36-51.24-32.93-59.09-47.33-36.31
Working Capital Days-168.98-88.24-124.87-56.81-36.86-51.2337.10
ROCE %25.21%1.60%65.84%60.41%11.27%8.70%

Continue your research

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre (Q2 FY27)

    Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves

  • Shalby (Q2 FY27)

    Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S

  • Metropolis Healt (Q2 FY27)

    Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre

  • Nephrocare Health Services (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health